Results 31 to 40 of about 152,178 (350)

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016) [PDF]

, 2018
Background: Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines.
Daniels, Benjamin, Girosi, Federico, Houssami, Nehmat, Kiely, Belinda E, Lord, Sarah J, Pearson, Sally-Anne, Tervonen, Hanna   +6 more
core   +2 more sources

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

JAMA Oncology, 2021
This phase 3 randomized clinical trial compares the clinical efficacy of margetuximab vs trastuzumab, each with chemotherapy, in patients with pretreated ERBB2-positive advanced breast cancer.
H. Rugo, S. Im, F. Cardoso, J. Cortés, G. Curigliano, A. Musolino, M. Pegram, G. Wright, C. Saura, S. Escrivá-de-Romaní, M. De Laurentiis, C. Lévy, U. Brown-Glaberman, J. Ferrero, M. de Boer, Sung-Bae Kim, K. Petráková, D. Yardley, O. Freedman, E. Jakobsen, B. Kaufman, R. Yerushalmi, P. Fasching, J. Nordstrom, E. Bonvini, S. Koenig, Sutton Edlich, Shengyan Hong, E. Rock, W. Gradishar   +29 more
semanticscholar   +1 more source

Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study

Scientific Reports, 2022
Adjuvant trastuzumab has been associated with superior survival in women with ≥ T1c or node-positive HER2-positive early-stage breast cancer; however, there is a lack of phase III trials in women with T1a/bN0 disease.
Sanji Ali, Jace Hendry, Duc Le, Prosanta K. Mondal, Amer Sami, Haji Chalchal, Kamal Haider, Osama Ahmed, Ali El-Gayed, Philip Wright, Mehrnoosh Pauls, Kate Johnson, Shahid Ahmed   +12 more
doaj   +1 more source

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review

Frontiers in Pharmacology, 2023
Background: Studies confirmed that trastuzumab plus fluorouracil-based chemotherapy improves the survival to more than 1 year in human with human epidermal growth factor receptor-2 (HER2)-positive advanced gastric cancer. However, there are still a small
Huifang Lv, Yunduan He, Caiyun Nie, Feng Du, Xiaobing Chen   +4 more
doaj   +1 more source

Regioselective and stoichiometrically controlled conjugation of photodynamic sensitizers to a HER2 targeting antibody fragment [PDF]

, 2014
The rapidly increasing interest in the synthesis of antibody–drug conjugates as powerful targeted anticancer agents demonstrates the growing appreciation of the power of antibodies and antibody fragments as highly selective targeting moieties.
Boyle, Ross W., Bryden, Francesca, Caddick, Stephen, Chudasama, Vijay, Maruani, Antoine, Savoie, Huguette, Smith, Mark E. B.   +6 more
core   +1 more source

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. [PDF]

, 2014
IntroductionThe purpose of this study was to retrospectively explore the relationship between human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) expression and efficacy in patients receiving trastuzumab plus docetaxel (HT) or ...
Amler, Lukas C, Gianni, Luca, Guardino, Ellie, Hurvitz, Sara A, Mundt, Kirsten E, Ng, Vivian, Perez, Edith A   +6 more
core   +9 more sources

Neoadjuvant therapy for early human epidermal growth factor receptor 2 positive breast cancer in China: A multicenter real-world study (CSBrS-015)

Chinese Medical Journal, 2022
. Background:. Pertuzumab has been approved for application in China by the National Medical Products Administration, and both national and international guidelines make recommendations for the use of neoadjuvant treatment with trastuzumab or trastuzumab
Yuanjia Cheng, Hongyu Xiang, Ling Xin, Xuening Duan, Yinhua Liu, Yuanyuan Ji, Chinese Society of Breast Surgery (CSBrS), Chinese Society of Surgery of Chinese Medical Association   +6 more
doaj   +1 more source

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]

, 2015
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F, Ahmed, R, Asher, R, Beresford, M, De Azambuja, E, Gojis, O, Howell, SJ, Januszewski, A, Lewanski, C, Lythgoe, D, Macpherson, IRJ, Owadally, W, Palmieri, C, Riddle, P, Shah, D, Stanley, B, Yan, K   +16 more
core   +2 more sources

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft

Cell Death Discovery, 2022
Acquired Trastuzumab resistance is a complicated and disastrous event for HER2-positive gastric cancer (GC). In this study, we successfully established a GC PDX model with Trastuzumab sensitivity (176P) and induced a homologous model with acquired ...
Mengqi Zhang, Beifang Li, Haiyan Liao, Zuhua Chen, Wenwen Huang, Jing Yang, Sai Ge, Zhongwu Li, Lin Shen, Cheng Zhang, Jing Gao   +10 more
doaj   +1 more source